Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder

Trial Profile

Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications Lipid metabolism disorders
  • Focus Therapeutic Use
  • Sponsors Ultragenyx Pharmaceutical
  • Most Recent Events

    • 27 Jul 2017 According to Ultragenyx media release, the company continue to plans for discussion with the regulatory authorities.
    • 15 Oct 2015 New trial record
    • 13 Oct 2015 According to Ultragenyx media release, design and timing of this study will be provided after discussion with the regulatory authorities in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top